EP2591805A1 - Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members - Google Patents
Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members Download PDFInfo
- Publication number
- EP2591805A1 EP2591805A1 EP13154400.9A EP13154400A EP2591805A1 EP 2591805 A1 EP2591805 A1 EP 2591805A1 EP 13154400 A EP13154400 A EP 13154400A EP 2591805 A1 EP2591805 A1 EP 2591805A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- egfr
- compound
- treatment
- pertuzumab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of specific pyrimidine derivatives in the treatment of Epidermal Growth Factor Receptor (EGFR) family members (including EGFR1 also known as HER1 or Erb-B1; EGFR2 also known as HER2 or Erb-B2; and EGFR3 also known as HER3 or Erb-B3) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds, and pharmaceutical preparations for the treatment of said diseases comprising said compounds, alone or in combination, especially with an EGFR modulator.
- EGFR Epidermal Growth Factor Receptor
- Somatic mutations in the tyrosine kinase domain of EGFR has been associated with the clinical response to EGFR tyrosine kinase inhibitor such as Gefitinib (Iressa®) or Erlotinib (Tarceva®) ( Paez et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, science, vol 304, 1497-1500 ). Acquired resistance to EGFR modulators occurs in patients who initially responded clinically to therapy, but then developed progressive tumors.
- EGFR tyrosine kinase inhibitor such as Gefitinib (Iressa®) or Erlotinib (Tarceva®)
- Refractory response to EGFR kinase inhibitors is exemplified with the secondary resistant mutation T790M ( Kobayashi et al.; EGFR mutation and resistance of non-small cell lung cancer to gefitinib, N. Engl J Med, Vol 352, 786-792 ), which is comparable to the resistance mutation(s) observed for Gleevec/Glivec or Dasatinib in chronic myelogenous leukemia (CML) ( Gorre et al.; Bcr-Abl point mutants isolated from patients with imatinib mesylate resistant chronic leukemia reamin sensitive to inhibitors of the Bcr-Abl chaperone heat shock protein 90, Blood, vol 100, 3041-3044 ) or GIST patients ( Antonescu et al.; Acquired resistance to Imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation, Clin Cancer Res, Vol 11, 4182-4190 ).
- T790M Kobayashi et al.; EGFR
- HER3 (ErbB-3), one of the four member of the EGFR family and partner of HER1 (EGFR1) is often overexpressed in EGFR inhibitors sensitive tumors, and that is correlated with constitutive PI3K recruitment and activation ( Engelman et al.; ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non small cell lung cancer cell lines, PNAS vol 102, 3788-3793 ; Sergina et al.; Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER 3 ).
- pyrimidine derivatives which are suitable for the present invention, their preparation and suitable pharmaceutical formulations containing the same are described in WO07/084786 and include compounds of formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt thereof, wherein, W is CR w or N, wherein R w is selected from the group consisting of
- R 1 is selected from the group consisting of
- R 2 is selected from the group consisting of
- R 3 is selected from the group consisting of
- R 4 is selected from the group consisting of
- a preferred compound of the present invention is a compound which is specifically described in WO07/084786 .
- a very preferred compound of the present invention is 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A).
- the synthesis of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine is described in WO07/084786 as Example 10.
- Target members of the EGFR family include EGFR family kinase modulators, compounds that alter EGFR expression levels or elicit a cellular immune reponse linked to the expression of EGFR family members in the tumor cells.
- Preferrable EGFR modulators exhibit their activity as inhibitors of EGFR functional activity.
- Target members of the EGFR family include without limitation gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IP1504, SNX5422 and NVP-AUY922.
- Non small cell lung carcinoma cell lines with EGFR mutant forms, but refractory to EGFR inhibition therapy, are valuable models to test the sensitivity of PI3K inhibitors like the compounds of formula I in such genetic background.
- the NCI-H1975 cell line is such a model as is highly tumorigenic in vivo.
- it contains HER1 bearing the T790M gatekeeper mutation that renders the kinase resistant to catalytic inhibition by compounds such as gefitinib.
- the in vivo antitumor activity of PI3K inhibitors like the compounds of formula I is tested against this EGFR driven and EGFR tyrosine kinase inhibitor resistant tumor model ( Figure 1 ).
- Surprisingly administration of Compound A causes in vivo tumor growth inhibition.
- Compound A is well tolerated - no statistically significant difference in body weight between the control and treatment groups can be observed ( Figure 2 ).
- a compound of formula I is therefore useful for the treatment of such EGFR dependent diseases, especially malignancies, or EGFR family members acquired resistance driven diseases.
- Diseases or malignancies with an established or potential molecular link to dysregulation of EGFR activity are, for instance, described in " Mendelsohn and Baselga; Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer, Journal of Clinical Oncology, 2787-2799 "; “ Mendelsohn and Baselga; Epidermal Growth Factor Receptor Targeting in Cancer, Seminars in Oncology, Vol 33, 369-385 "; Irmer et al., EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy, Oncogene, 1-9 ; Roche-Lima et al., EGFR targeting of solid tumors; Cancer Control, 2007, Vol 14 (3), 295-304 ) which all are, including the references cited therein, hereby incorporated into the present application by reference
- the present invention relates to the use of acompound of formula I as described above, or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof for the manufacture of a pharmaceutical preparation for the treatment of an EGFR dependent disease.
- the present invention relates to the use of a compound of formula I, especially 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-yamine for the manufacture of a pharmaceutical preparation for the treatment of an EGFR dependent disease or malignancy or a disease that has acquired resistance to agents that target EGFR family members.
- the resistance to the treatment with an EGFR modulator can been acquired during treatment with said EGFR modulator or can be due to a mutation or mutations in the protein.
- the present invention relates to the treatment of a disease or malignancy that is dependent on EGFR family members or has aquired resistance during treatment with an EGFR modulator, with compounds of formula I, especially Compound A or a pharmaceutically acceptable salt thereof.
- EGFR modulators that upon treatment can result in resistance are, for instance, gefitinib, erlotinib, lapatinib, cetuximab, nimotuzumab, panitumumab, and trastuzumab.
- a compound of the formula (I) may also be used for the treatment of EGFR dependent or EGFR acquired resistance diseases in combination with other active compounds for instance the combination partners as disclosed in WO07/084786 , more preferred EGFR family targeting agents such us, and without limitation to gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010,
- the present invention also relates to a combination treatment of EGFR dependent diseases with a compounds of formula I, especially of a compound selected from the group consisting of (Compound A) and an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tane
- the present invention relates to a combination of compound of formula I selected from the group consisting of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine and an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, cetuximab, nimotuzumab, panitumumab, and trastuzumab, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use for the treatment of non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and ovarian cancer.
- an EGFR modulator selected from the group consisting of
- the present invention relates to a method of treating an EGFR dependent disease or a malignancy, preferably a malignancy, that has acquired resistance to EGFR kinase modulators during treatment with said EGFR modulator, comprising administering a therapeutically effective amount of a specific imidazoquinoline derivative of formula I, especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A) or a pharmaceutically acceptable salt thereof, alone or in combination with an EGFR modulator, to a warm-blooded animal in need thereof.
- a specific imidazoquinoline derivative of formula I especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A) or a pharmaceutically acceptable salt thereof, alone or in combination with an EGFR modulator, to a warm-blooded animal in need thereof
- the diseases to be treated by this method are preferentially non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and ovarian cancer.
- the present invention relates to a pharmaceutical preparation for the treatment of an EGFR dependent disease or a disease that has acquired resistance during treatment with an EGFR modulator comprising a compound of formula I, especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, alone or in combination with an EGFR modulator.
- a pharmaceutical preparation for the treatment of an EGFR dependent disease or a disease that has acquired resistance during treatment with an EGFR modulator comprising a compound of formula I, especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, alone or in combination with an EGFR modulator.
- the diseases to be treated by this pharmaceutical preparation are preferentially non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and ovarian cancer.
- the present invention relates to the use of a compound of formula I, especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-y lamine (Compound A) or a pharmaceutically acceptable salt thereof for the treatment of an EGFR dependent disease or disease that has acquired resistance during treatment with an EGFR modulator.
- a compound of formula I especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-y lamine (Compound A) or a pharmaceutically acceptable salt thereof for the treatment of an EGFR dependent disease or disease that has acquired resistance during treatment with an EGFR modulator.
- the diseases to be treated by this compounds are preferentially non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and ovarian cancer.
- a compound of the formula (I) may also be used to advantage in combination with known therapeutic processes, for example, hormone therapy or, especially, radiation.
- a compound of formula (I) may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
- Treatment in accordance with the invention may be symptomatic or prophylactic.
- ком ⁇ онент there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g. synergistic effect.
- a compound of formula I can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds.
- the dosage of the active ingredient depends upon a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed.
- a physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
- Optimal precision in achieving concentration of drug within the range that yields efficacy requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
- the compounds of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, e.g. orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form.
- Topical administration is e.g. to the skin.
- a further form of topical administration is to the eye.
- Pharmaceutical compositions comprising a compound of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
- compositions are comprising an amount effective in the treatment of one of the above-mentioned disorders, of a compound of formula I or an N-oxide or a tautomer thereof together with pharmaceutically acceptable carriers that are suitable for topical, enteral, for example oral or rectal, or parenteral administration and that may be inorganic or organic, solid or liquid.
- pharmaceutical compositions used for oral administration especially tablets or gelatin capsules that comprise the active ingredient together with diluents, for example lactose, dextrose, manitol, and/or glycerol, and/or lubricants and/or polyethylene glycol.
- Tablets may also comprise binders, for example magnesium aluminum silicate, starches, such as corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorbents, dyes, flavorings and sweeteners. It is also possible to use the pharmacologically active compounds of the present invention in the form of parenterally administrable compositions or in the form of infusion solutions.
- binders for example magnesium aluminum silicate, starches, such as corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone
- disintegrators for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or
- the pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting compounds and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
- excipients for example preservatives, stabilizers, wetting compounds and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers.
- the present pharmaceutical compositions which may, if desired, comprise other pharmacologically active substances are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising lyophilizing processes, and comprise approximately from 1% to 99%, especially from approximately 1% to approximately 20%, active ingredient(s).
- the present invention also provides the following embodiments as described in the following Paragraphs.
Abstract
Description
- The present invention relates to the use of specific pyrimidine derivatives in the treatment of Epidermal Growth Factor Receptor (EGFR) family members (including EGFR1 also known as HER1 or Erb-B1; EGFR2 also known as HER2 or Erb-B2; and EGFR3 also known as HER3 or Erb-B3) dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with EGFR modulators for said use, methods of treating said diseases with said compounds, and pharmaceutical preparations for the treatment of said diseases comprising said compounds, alone or in combination, especially with an EGFR modulator.
- Somatic mutations in the tyrosine kinase domain of EGFR has been associated with the clinical response to EGFR tyrosine kinase inhibitor such as Gefitinib (Iressa®) or Erlotinib (Tarceva®) ( Paez et al., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, science, vol 304, 1497-1500 ). Acquired resistance to EGFR modulators occurs in patients who initially responded clinically to therapy, but then developed progressive tumors. Refractory response to EGFR kinase inhibitors is exemplified with the secondary resistant mutation T790M ( Kobayashi et al.; EGFR mutation and resistance of non-small cell lung cancer to gefitinib, N. Engl J Med, Vol 352, 786-792), which is comparable to the resistance mutation(s) observed for Gleevec/Glivec or Dasatinib in chronic myelogenous leukemia (CML) ( Gorre et al.; Bcr-Abl point mutants isolated from patients with imatinib mesylate resistant chronic leukemia reamin sensitive to inhibitors of the Bcr-Abl chaperone heat shock protein 90, Blood, ) or GIST patients ( Antonescu et al.; Acquired resistance to Imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation, Clin Cancer Res, Vol 11, 4182-4190 ).
- Evidences that activation of the PI3K pathway downstream of activated EGFR exists in the literature. Thus, genetic ablation of the PI3K catalytic subunit (p110) in mouse embryo fibroblast renders cells resistant for transformation by an activated form of EGFR ( Zhao et al.; The p110 alpha isoform of P13K is essential for proper growth factor signaling and oncogenic transformation, PNAS, vol 103, 16296-16300 ). HER3 (ErbB-3), one of the four member of the EGFR family and partner of HER1 (EGFR1) is often overexpressed in EGFR inhibitors sensitive tumors, and that is correlated with constitutive PI3K recruitment and activation ( Engelman et al.; ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non small cell lung cancer cell lines, PNAS vol 102, 3788-3793; Sergina et al.; Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER 3). The genetic and biochemical characterization of tumor biopsies and tumor cell lines harboring EGFR amplification and EGFR inhibitor resistance have revealed a constitutive activation status of the PI3K pathway ( Engelman et al.; Allelic disruption obscures detection of a biologically significant resistance mutation in EGFR amplified lung cancer, The Journal of Clinical Investigation, vol 116, 2695-2706).
- Surprisingly, it has been found that specific pyrimidine derivatives, which have been described in
WO07/084786 - Specific pyrimidine derivatives which are suitable for the present invention, their preparation and suitable pharmaceutical formulations containing the same are described in
WO07/084786 - (1)
- hydrogen,
- (2)
- cyano,
- (3)
- halogen,
- (4)
- methyl,
- (5)
- trifluoromethyl,
- (6)
- sulfonamido;
- R1 is selected from the group consisting of
- (1)
- hydrogen,
- (2)
- cyano,
- (3)
- nitro,
- (4)
- halogen,
- (5)
- substituted and unsubstituted alkyl,
- (6)
- substituted and unsubstituted alkenyl,
- (7)
- substituted and unsubstituted alkynyl,
- (8)
- substituted and unsubstituted aryl,
- (9)
- substituted and unsubstituted heteroaryl,
- (10)
- substituted and unsubstituted heterocyclyl,
- (11)
- substituted and unsubstituted cycloalkyl,
- (12)
- -COR1a,
- (13)
- -CO2R1a,
- (14)
- -CONR1aR1b,
- (15)
- -NR1aR1b,
- (16)
- -NR1aCOR1b,
- (17)
- -NR1aSO2R1b,
- (18)
- -OCOR1a,
- (19)
- -OR1a,
- (20)
- -SR1a,
- (21)
- -SOR1a,
- (22)
- -SO2R1a, and
- (23)
- -SO2NR1aR1b,
- (a)
- hydrogen,
- (b)
- substituted or unsubstituted alkyl,
- (c)
- substituted and unsubstituted aryl,
- (d)
- substituted and unsubstituted heteroaryl,
- (e)
- substituted and unsubstituted heterocyclyl, and
- (f)
- substituted and unsubstituted cycloalkyl;
- R2 is selected from the group consisting
- (1)
- hydrogen,
- (2)
- cyano,
- (3)
- nitro,
- (4)
- halogen,
- (5)
- hydroxy,
- (6)
- amino,
- (7)
- substituted and unsubstituted alkyl,
- (8)
- -COR2a, and
- (9)
- -NR2aCOR2b,
- (a)
- hydrogen, and
- (b)
- substituted or unsubstituted alkyl;
- R3 is selected from the group consisting of
- (1)
- hydrogen,
- (2)
- cyano,
- (3)
- nitro,
- (4)
- halogen,
- (5)
- substituted and unsubstituted alkyl,
- (6)
- substituted and unsubstituted alkenyl,
- (7)
- substituted and unsubstituted alkynyl,
- (8)
- substituted and unsubstituted aryl,
- (9)
- substituted and unsubstituted heteroaryl,
- (10)
- substituted and unsubstituted heterocyclyl,
- (11)
- substituted and unsubstituted cycloalkyl,
- (12)
- -COR3a,
- (13)
- -NR3aR3b,
- (14)
- -NR3aCOR3b,
- (15)
- -NR3aSO2R3b,
- (16)
- -OR3a,
- (17)
- -SR3a,
- (18)
- -SOR3a,
- (19)
- -SO2R3a, and
- (20)
- -SO2NR3aR3b,
- (a)
- hydrogen,
- (b)
- substituted or unsubstituted alkyl,
- (c)
- substituted and unsubstituted aryl,
- (d)
- substituted and unsubstituted heteroaryl,
- (e)
- substituted and unsubstituted heterocyclyl, and
- (f)
- substituted and unsubstituted cycloalkyl; and
- R4 is selected from the group consisting of
- (1)
- hydrogen, and
- (2)
- halogen.
- The radicals and symbols as used in the definition of a compound of formula I have the meanings as disclosed in
WO07/084786 - A preferred compound of the present invention is a compound which is specifically described in
WO07/084786 - A very preferred compound of the present invention is 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A). The synthesis of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine is described in
WO07/084786 - Compounds that target members of the EGFR family according to the present invention include EGFR family kinase modulators, compounds that alter EGFR expression levels or elicit a cellular immune reponse linked to the expression of EGFR family members in the tumor cells. Preferrable EGFR modulators exhibit their activity as inhibitors of EGFR functional activity. Compounds that target members of the EGFR family according to the present invention include without limitation gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IP1504, SNX5422 and NVP-AUY922.
-
-
Figure 1 shows the antitumor activity of Compound A against the EGFR inhibitor resistant NSCLC cell line NCI-H1975.
Female Harlan athymic mice (n = 6), bearing s.c NCI-H1975 tumors are treated p.o. with the PI3K inhibitor Compound A at 50mg/kg every day for the duration of the treatment. * p<0.05 (Dunnet's vs controls). -
Figure 2 shows the mean body weight of vehicle and Compound A treated groups during the efficacy in vivo study performed with mice bearing the s.c. the EGFR inhibitor resistant NSCLC cell line NCI-H1975. - Non small cell lung carcinoma cell lines with EGFR mutant forms, but refractory to EGFR inhibition therapy, are valuable models to test the sensitivity of PI3K inhibitors like the compounds of formula I in such genetic background. The NCI-H1975 cell line is such a model as is highly tumorigenic in vivo. Moreover, it contains HER1 bearing the T790M gatekeeper mutation that renders the kinase resistant to catalytic inhibition by compounds such as gefitinib. The in vivo antitumor activity of PI3K inhibitors like the compounds of formula I is tested against this EGFR driven and EGFR tyrosine kinase inhibitor resistant tumor model (
Figure 1 ). Surprisingly administration of Compound A causes in vivo tumor growth inhibition. Compound A is well tolerated - no statistically significant difference in body weight between the control and treatment groups can be observed (Figure 2 ). - A compound of formula I, especially Compound A, is therefore useful for the treatment of such EGFR dependent diseases, especially malignancies, or EGFR family members acquired resistance driven diseases. Diseases or malignancies with an established or potential molecular link to dysregulation of EGFR activity are, for instance, described in " Mendelsohn and Baselga; Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer, Journal of Clinical Oncology, 2787-2799"; " Mendelsohn and Baselga; Epidermal Growth Factor Receptor Targeting in Cancer, Seminars in Oncology, "; Irmer et al., EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy, Oncogene, 1-9 ; Roche-Lima et al., EGFR targeting of solid tumors; Cancer Control, 2007, Vol 14 (3), 295-304 ) which all are, including the references cited therein, hereby incorporated into the present application by reference.
- According to the present invention the treatment of the following EGFR dependent diseases, especially malignancies, with compounds of formula I, especially Compound A, is preferred:
- non small cell lung carcinoma
- head and neck cancer
- colorectal carcinoma
- breast cancer
- brain malignancies including glioblastoma
- prostate cancer
- bladder cancer
- renal cell carcinoma
- pancreas cancer
- cervical cancer
- esophageal cancer
- gastric cancer
- ovarian cancer
- The present invention relates to the use of acompound of formula I as described above, or a tautomer thereof, or a pharmaceutically acceptable salt, or a hydrate or solvate thereof for the manufacture of a pharmaceutical preparation for the treatment of an EGFR dependent disease.
- Furthermore, the present invention relates to the use of a compound of formula I, especially 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-yamine for the manufacture of a pharmaceutical preparation for the treatment of an EGFR dependent disease or malignancy or a disease that has acquired resistance to agents that target EGFR family members.
- The resistance to the treatment with an EGFR modulator can been acquired during treatment with said EGFR modulator or can be due to a mutation or mutations in the protein.
- In particular, the present invention relates to the treatment of a disease or malignancy that is dependent on EGFR family members or has aquired resistance during treatment with an EGFR modulator, with compounds of formula I, especially Compound A or a pharmaceutically acceptable salt thereof. Possible EGFR modulators that upon treatment can result in resistance are, for instance, gefitinib, erlotinib, lapatinib, cetuximab, nimotuzumab, panitumumab, and trastuzumab.
- A compound of the formula (I) may also be used for the treatment of EGFR dependent or EGFR acquired resistance diseases in combination with other active compounds for instance the combination partners as disclosed in
WO07/084786 - The present invention also relates to a combination treatment of EGFR dependent diseases with a compounds of formula I, especially of a compound selected from the group consisting of (Compound A) and an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use for the treatment of non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and/or ovarian cancer
- In particular, the present invention relates to a combination of compound of formula I selected from the group consisting of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine and an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, cetuximab, nimotuzumab, panitumumab, and trastuzumab, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use for the treatment of non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and ovarian cancer.
- In another embodiment the present invention relates to a method of treating an EGFR dependent disease or a malignancy, preferably a malignancy, that has acquired resistance to EGFR kinase modulators during treatment with said EGFR modulator, comprising administering a therapeutically effective amount of a specific imidazoquinoline derivative of formula I, especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A) or a pharmaceutically acceptable salt thereof, alone or in combination with an EGFR modulator, to a warm-blooded animal in need thereof.
- The diseases to be treated by this method are preferentially non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and ovarian cancer.
- In another embodiment the present invention relates to a pharmaceutical preparation for the treatment of an EGFR dependent disease or a disease that has acquired resistance during treatment with an EGFR modulator comprising a compound of formula I, especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A) or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier, alone or in combination with an EGFR modulator.
- The diseases to be treated by this pharmaceutical preparation are preferentially non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and ovarian cancer.
- In another embodiment the present invention relates to the use of a compound of formula I, especially preferred 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-y lamine (Compound A) or a pharmaceutically acceptable salt thereof for the treatment of an EGFR dependent disease or disease that has acquired resistance during treatment with an EGFR modulator.
- The diseases to be treated by this compounds, alone or in combination with an EGFR modulator, are preferentially non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and ovarian cancer.
- A compound of the formula (I) may also be used to advantage in combination with known therapeutic processes, for example, hormone therapy or, especially, radiation. A compound of formula (I) may in particular be used as a radiosensitizer, especially for the treatment of tumors which exhibit poor sensitivity to radiotherapy.
- Treatment in accordance with the invention may be symptomatic or prophylactic.
- By "combination", there is meant either a fixed combination in one dosage unit form, or a kit of parts for the combined administration where a compound of the formula (I) and a combination partner may be administered independently at the same time or separately within time intervals that especially allow that the combination partners show a cooperative, e.g. synergistic effect.
- A compound of formula I can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds.
- The dosage of the active ingredient depends upon a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound employed. A physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition. Optimal precision in achieving concentration of drug within the range that yields efficacy requires a regimen based on the kinetics of the drug's availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of a drug.
- The compounds of the invention may be administered by any conventional route, in particular parenterally, for example in the form of injectable solutions or suspensions, enterally, e.g. orally, for example in the form of tablets or capsules, topically, e.g. in the form of lotions, gels, ointments or creams, or in a nasal or a suppository form. Topical administration is e.g. to the skin. A further form of topical administration is to the eye. Pharmaceutical compositions comprising a compound of the invention in association with at least one pharmaceutical acceptable carrier or diluent may be manufactured in conventional manner by mixing with a pharmaceutically acceptable carrier or diluent.
- The pharmaceutical compositions are comprising an amount effective in the treatment of one of the above-mentioned disorders, of a compound of formula I or an N-oxide or a tautomer thereof together with pharmaceutically acceptable carriers that are suitable for topical, enteral, for example oral or rectal, or parenteral administration and that may be inorganic or organic, solid or liquid. There are pharmaceutical compositions used for oral administration especially tablets or gelatin capsules that comprise the active ingredient together with diluents, for example lactose, dextrose, manitol, and/or glycerol, and/or lubricants and/or polyethylene glycol. Tablets may also comprise binders, for example magnesium aluminum silicate, starches, such as corn, wheat or rice starch, gelatin, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone, and, if desired, disintegrators, for example starches, agar, alginic acid or a salt thereof, such as sodium alginate, and/or effervescent mixtures, or adsorbents, dyes, flavorings and sweeteners. It is also possible to use the pharmacologically active compounds of the present invention in the form of parenterally administrable compositions or in the form of infusion solutions. The pharmaceutical compositions may be sterilized and/or may comprise excipients, for example preservatives, stabilizers, wetting compounds and/or emulsifiers, solubilisers, salts for regulating the osmotic pressure and/or buffers. The present pharmaceutical compositions, which may, if desired, comprise other pharmacologically active substances are prepared in a manner known per se, for example by means of conventional mixing, granulating, confectioning, dissolving or lyophilising lyophilizing processes, and comprise approximately from 1% to 99%, especially from approximately 1% to approximately 20%, active ingredient(s).
- The present invention also provides the following embodiments as described in the following Paragraphs.
-
- 1. Use of a compound of formula I,
- (1)
- hydrogen,
- (2)
- cyano,
- (3)
- halogen,
- (4)
- methyl,
- (5)
- trifluoromethyl,
- (6)
- sulfonamido;
- (1)
- hydrogen,
- (2)
- cyano,
- (3)
- nitro,
- (4)
- halogen,
- (5)
- substituted and unsubstituted alkyl,
- (6)
- substituted and unsubstituted alkenyl,
- (7)
- substituted and unsubstituted alkynyl,
- (8)
- substituted and unsubstituted aryl,
- (9)
- substituted and unsubstituted heteroaryl,
- (10)
- substituted and unsubstituted heterocyclyl,
- (11)
- substituted and unsubstituted cycloalkyl,
- (12)
- -COR1a,
- (13)
- -CO2R1a,
- (14)
- -CONR1aR1b,
- (15)
- -NR1aR1b,
- (16)
- -NR1aCOR1b,
- (17)
- -NR1aSO2R1b,
- (18)
- -OCOR1a,
- (19)
- -OR1a,
- (20)
- -SR1a,
- (21)
- -SOR1a,
- (22)
- -SO2R1a, and
- (23)
- -SO2NR1aR1b,
- (a)
- hydrogen,
- (b)
- substituted or unsubstituted alkyl,
- (c)
- substituted and unsubstituted aryl,
- (d)
- substituted and unsubstituted heteroaryl,
- (e)
- substituted and unsubstituted heterocyclyl, and
- (f)
- substituted and unsubstituted cycloalkyl;
- (1)
- hydrogen,
- (2)
- cyano,
- (3)
- nitro,
- (4)
- halogen,
- (5)
- hydroxy,
- (6)
- amino,
- (7)
- substituted and unsubstituted alkyl,
- (8)
- -COR2a, and
- (9)
- -NR2aCOR2b,
- (a)
- hydrogen, and
- (b)
- substituted or unsubstituted alkyl;
- (1)
- hydrogen,
- (2)
- cyano,
- (3)
- nitro,
- (4)
- halogen,
- (5)
- substituted and unsubstituted alkyl,
- (6)
- substituted and unsubstituted alkenyl,
- (7)
- substituted and unsubstituted alkynyl,
- (8)
- substituted and unsubstituted aryl,
- (9)
- substituted and unsubstituted heteroaryl,
- (10)
- substituted and unsubstituted heterocyclyl,
- (11)
- substituted and unsubstituted cycloalkyl,
- (12)
- -COR3a,
- (13)
- -NR3aR3b,
- (14)
- -NR3aCOR3b,
- (15)
- -NR3aSO2R3b,
- (16)
- -OR3a,
- (17)
- -SR3a,
- (18)
- -SOR3a,
- (19)
- -SO2R3a, and
- (20)
- -SO2NR3aR3b,
- (a)
- hydrogen,
- (b)
- substituted or unsubstituted alkyl,
- (c)
- substituted and unsubstituted aryl,
- (d)
- substituted and unsubstituted heteroaryl,
- (e)
- substituted and unsubstituted heterocyclyl, and
- (f)
- substituted and unsubstituted cycloalkyl; and
- (1)
- hydrogen, and
- (2)
- halogen;
- 2. The use according to Paragraph 1, where the compound of the formula I is 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-yamine (Compound A).
- 3. The use according to any one of Paragraphs 1 to 2, wherein the disease is a malignancy.
- 4. The use according to any one of Paragraphs 1 to 3, wherein said disease is resistant to the treatment with an EGFR modulator.
- 5. The use according to Paragraph 4, wherein resistance to the treatment with an EGFR modulator has been acquired during treatment with said EGFR modulator.
- 6. The use according to Paragraph 4, wherein the resistance is due to exon deletions and / or a mutation or mutations in the protein.
- 7. The use according to Paragraph 4 or 5, wherein the EGFR modulator is selected from the group consisting of gefitinib, erlotinib, lapatinib, cetuximab, nimotuzumab, panitumumab and trastuzumab.
- 8. The use according to any one of Paragraphs 1 to 3, together with an EGFR modulator.
- 9. The use according to Paragraph 8, wherein the EGFR modulator is selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922.
- 10. The use according to any one of Paragraphs 1 to 9, wherein the disease to be treated is
- non small cell lung carcinoma
- head and neck cancer
- colorectal carcinoma
- breast cancer
- brain malignancies including glioblastoma
- prostate cancer
- bladder cancer
- renal cell carcinoma
- pancreas cancer
- cervical cancer
- esophageal cancer
- gastric cancer
- ovarian cancer
or any combination thereof.
- 11. Combination of a compound of formula I selected from the group consisting of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A) and an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use for the treatment of non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and/or ovarian cancer.
- 12. A method of treating an EGFR dependent disease or a disease that has acquired resistance during treatment with an EGFR modulator comprising administering a therapeutically effective amount of a compound of formula I, according to any one of Paragraphs 1 to 2, to a warm-blooded animal in need thereof.
- 13. The method according to Paragraph 13, wherein the disease to be treated is a disease according to Paragraph 10.
- 14. The method according to Paragraph 12 or 13, wherein the compound of formula I is administered together with an EGFR modulator according to Paragraph 9.
- 15. A pharmaceutical preparation for the treatment of an EGFR dependent disease or a disease that has acquired resistance during treatment with an EGFR modulator comprising a compound of formula I, according to any one of Paragraphs 1 to 2 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.
- 16. The pharmaceutical preparation according to Paragraph 15, wherein the disease to be treated is a disease according to Paragraph 10.
- 17. The pharmaceutical preparation according to Paragraph 15 or 16, comprising an EGFR modulator according to Paragraph 9.
- 18. Use of a compound of formula I, according to any one of Paragraphs 1 to 2 or a pharmaceutically acceptable salt thereof for the treatment of an EGFR dependent disease or disease that has acquired resistance during treatment with an EGFR modulator.
- 19. The use according to
Paragraph 18, wherein the disease to be treated is a disease according to Paragraph 10. - 20. The use according to
Paragraph
Claims (11)
- The compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine or a pharmaceutically acceptable salt thereof for use in the treatment of an EGFR dependent disease, wherein the EGFR dependent disease is• breast cancer• non small cell lung carcinoma• head and neck cancer• colorectal carcinoma• brain malignancies including glioblastoma• prostate cancer• bladder cancer• renal cell carcinoma• pancreas cancer• cervical cancer• esophageal cancer• gastric cancer• ovarian cancer
or any combination thereof. - The compound for use according to claim 1, wherein the disease is a malignancy.
- The compound for use according to any one of claims 1 or 2, wherein said disease is resistant to the treatment with an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922.
- The compound for use according to any one of claims 1 or 2, wherein said disease is resistant to the treatment with an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, cetuximab, nimotuzumab, panitumumab and trastuzumab.
- The compound for use according to any one of claims 3 or 4, wherein resistance to the treatment with an EGFR modulator has been acquired during treatment with said EGFR modulator.
- The compound for use according to claim 5, wherein the resistance is due to exon deletions and / or a mutation or mutations in the protein.
- The compound for use according to any one of claims 1 to 3, together with an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922.
- Combination of a compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine (Compound A) and an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, and optionally at least one pharmaceutically acceptable carrier, for simultaneous, separate or sequential use for the treatment of breast cancer, non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer and/or ovarian cancer.
- A compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment of an EGFR dependent disease or a disease that has acquired resistance during treatment with an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922, wherein the disease to be treated is breast cancer, non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, breast cancer, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer or ovarian cancer or any combination thereof.
- The compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine according to claim 1 or a pharmaceutically acceptable salt thereof for use in the treatment according to claim 9, wherein said compound is administered together with an EGFR modulator selected from the group consisting of gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922.
- A pharmaceutical preparation for use in the treatment of an EGFR dependent disease or a disease that has acquired resistance during treatment with an EGFR modulator selected the group consisting of from gefitinib, erlotinib, lapatinib, NVP-AEE778, ARRY334543, BIRW2992, BMS690514, pelitinib, vandetanib, AV412, anti-EGFR monoclonal antibody 806, anti-EGFR monoclonal antibody-Y90/Re-188, cetuximab, panitumumab, matuzumab, nimotuzumab, zalutumumab, pertuzumab, MDX-214, CDX110, IMC11F8, pertuzumab, trastuzumab, zemab®, the Her2 vaccine PX 1041, and the HSP90 inhibitors CNF1010, CNF2024, tanespimycinm alvespimycin, IPI504, SNX5422 and NVP-AUY922 and wherein the disease to be treated is breast cancer, non small cell lung carcinoma, head and neck cancer, colorectal carcinoma, brain malignancies including glioblastoma, prostate cancer, bladder cancer, renal cell carcinoma, pancreas cancer, cervical cancer, esophageal cancer, gastric cancer or ovarian cancer, or any combination thereof, comprising a compound 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine according to claim 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13154400.9A EP2591805A1 (en) | 2008-03-05 | 2009-03-04 | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08152326 | 2008-03-05 | ||
EP13154400.9A EP2591805A1 (en) | 2008-03-05 | 2009-03-04 | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
EP09716778.7A EP2259800B1 (en) | 2008-03-05 | 2009-03-04 | Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators. |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09716778.7A Division-Into EP2259800B1 (en) | 2008-03-05 | 2009-03-04 | Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators. |
EP09716778.7 Division | 2009-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2591805A1 true EP2591805A1 (en) | 2013-05-15 |
Family
ID=39343633
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13155903.1A Withdrawn EP2599499A1 (en) | 2008-03-05 | 2009-03-04 | Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
EP13154400.9A Withdrawn EP2591805A1 (en) | 2008-03-05 | 2009-03-04 | Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
EP09716778.7A Not-in-force EP2259800B1 (en) | 2008-03-05 | 2009-03-04 | Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators. |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP13155903.1A Withdrawn EP2599499A1 (en) | 2008-03-05 | 2009-03-04 | Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP09716778.7A Not-in-force EP2259800B1 (en) | 2008-03-05 | 2009-03-04 | Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators. |
Country Status (14)
Country | Link |
---|---|
US (2) | US20110033453A1 (en) |
EP (3) | EP2599499A1 (en) |
JP (2) | JP2011513364A (en) |
KR (1) | KR20100131446A (en) |
CN (2) | CN101959533A (en) |
AU (1) | AU2009221164B2 (en) |
BR (1) | BRPI0908049A2 (en) |
CA (1) | CA2716518A1 (en) |
ES (1) | ES2471452T3 (en) |
MX (1) | MX2010009743A (en) |
PL (1) | PL2259800T3 (en) |
PT (1) | PT2259800E (en) |
RU (2) | RU2496500C2 (en) |
WO (1) | WO2009109605A1 (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010534219A (en) * | 2007-07-24 | 2010-11-04 | ノバルティス アーゲー | Use of imidazoquinolines for the treatment of EGFR-dependent diseases or diseases that have acquired resistance to drugs targeting EGFR family members |
ES2645689T3 (en) | 2008-05-21 | 2017-12-07 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
CN103153064B (en) * | 2010-10-14 | 2015-04-22 | 阿里亚德医药股份有限公司 | Methods for inhibiting cell proliferation in EGFR-driven cancers |
KR101884010B1 (en) | 2011-05-04 | 2018-07-31 | 어리어드 파마슈티칼스, 인코포레이티드 | Compounds for inhibiting cell proliferation in egfr-driven cancers |
CA2849995A1 (en) | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
CN102397544A (en) * | 2011-11-25 | 2012-04-04 | 百泰生物药业有限公司 | Application of monoclonal antibody to treatment of non-small cell lung cancer |
UY34632A (en) | 2012-02-24 | 2013-05-31 | Novartis Ag | OXAZOLIDIN- 2- ONA COMPOUNDS AND USES OF THE SAME |
JP6469567B2 (en) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Compound for inhibiting cell proliferation of EGFR-activated cancer |
RU2705095C2 (en) * | 2012-08-16 | 2019-11-05 | Новартис Аг | Combination of pik3 inhibitor and inhibitor c-met |
US9296733B2 (en) | 2012-11-12 | 2016-03-29 | Novartis Ag | Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases |
GEP201706699B (en) | 2013-03-14 | 2017-07-10 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
WO2016092508A1 (en) * | 2014-12-12 | 2016-06-16 | Massachusetts General Hospital | Treatment of breast cancer brain metastases |
CN111529530B (en) * | 2020-04-02 | 2021-06-04 | 中山大学 | Application of pyridimidazoles STAT3 inhibitor in preparation of medicine for delaying or reversing acquired drug resistance of TKIs |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004048365A1 (en) * | 2002-11-21 | 2004-06-10 | Chiron Corporation | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
WO2007084786A1 (en) | 2006-01-20 | 2007-07-26 | Novartis Ag | Pyrimidine derivatives used as pi-3 kinase inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
EE200100603A (en) * | 1999-05-14 | 2003-02-17 | Imclone Systems Incorporated | Treatment of human refractory tumors with epidermal growth factor receptor antagonists |
JP2010534219A (en) * | 2007-07-24 | 2010-11-04 | ノバルティス アーゲー | Use of imidazoquinolines for the treatment of EGFR-dependent diseases or diseases that have acquired resistance to drugs targeting EGFR family members |
-
2009
- 2009-03-04 EP EP13155903.1A patent/EP2599499A1/en not_active Withdrawn
- 2009-03-04 CN CN200980107270XA patent/CN101959533A/en active Pending
- 2009-03-04 MX MX2010009743A patent/MX2010009743A/en active IP Right Grant
- 2009-03-04 CA CA2716518A patent/CA2716518A1/en not_active Abandoned
- 2009-03-04 EP EP13154400.9A patent/EP2591805A1/en not_active Withdrawn
- 2009-03-04 RU RU2010140435/15A patent/RU2496500C2/en not_active IP Right Cessation
- 2009-03-04 WO PCT/EP2009/052564 patent/WO2009109605A1/en active Application Filing
- 2009-03-04 BR BRPI0908049-0A patent/BRPI0908049A2/en not_active IP Right Cessation
- 2009-03-04 CN CN201510646346.3A patent/CN105343102A/en active Pending
- 2009-03-04 EP EP09716778.7A patent/EP2259800B1/en not_active Not-in-force
- 2009-03-04 US US12/867,058 patent/US20110033453A1/en not_active Abandoned
- 2009-03-04 JP JP2010549141A patent/JP2011513364A/en active Pending
- 2009-03-04 KR KR1020107019674A patent/KR20100131446A/en active IP Right Grant
- 2009-03-04 PL PL09716778T patent/PL2259800T3/en unknown
- 2009-03-04 ES ES09716778.7T patent/ES2471452T3/en active Active
- 2009-03-04 PT PT97167787T patent/PT2259800E/en unknown
- 2009-03-04 AU AU2009221164A patent/AU2009221164B2/en not_active Ceased
-
2013
- 2013-07-10 RU RU2013132018/15A patent/RU2013132018A/en not_active Application Discontinuation
- 2013-10-01 JP JP2013206606A patent/JP5778735B2/en not_active Expired - Fee Related
-
2014
- 2014-02-17 US US14/182,023 patent/US20140161722A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004048365A1 (en) * | 2002-11-21 | 2004-06-10 | Chiron Corporation | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
WO2007084786A1 (en) | 2006-01-20 | 2007-07-26 | Novartis Ag | Pyrimidine derivatives used as pi-3 kinase inhibitors |
Non-Patent Citations (12)
Title |
---|
"Mendelsohn and Baselga; Status of Epidermal Growth Factor Receptor Antagonists in the Biology and Treatment of Cancer", JOURNAL OF CLINICAL ONCOLOGY, pages 2787 - 2799 |
ANTONESCU: "Acquired resistance to Imatinib in gastrointestinal stromal tumors occurs through secondary gene mutation", CLIN CANCER RES, vol. 11, pages 4182 - 4190 |
ENGELMAN: "Allelic disruption obscures detection of a biologically significant resistance mutation in EGFR amplified lung cancer", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 116, pages 2695 - 2706, XP002498404, DOI: doi:10.1172/JCI28656 |
ENGELMAN: "ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non small cell lung cancer cell lines", PNAS, vol. 102, pages 3788 - 3793, XP055075919, DOI: doi:10.1073/pnas.0409773102 |
GORRE: "Bcr-Abl point mutants isolated from patients with imatinib mesylate resistant chronic leukemia reamin sensitive to inhibitors of the Bcr-Abl chaperone heat shock protein 90", BLOOD, vol. 100, pages 3041 - 3044, XP002983318, DOI: doi:10.1182/blood-2002-05-1361 |
IRMER ET AL.: "EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy", ONCOGENE, pages 1 - 9 |
KOBAYASHI: "EGFR mutation and resistance of non-small cell lung cancer to gefitinib", N. ENGL J MED, vol. 352, pages 786 - 792, XP002395764 |
MENDELSOHN JOHN ET AL: "Epidermal growth factor receptor targeting in cancer", SEMINARS IN ONCOLOGY, W.B. SAUNDERS, US, vol. 33, no. 4, 1 August 2006 (2006-08-01), pages 369 - 385, XP009096633, ISSN: 0093-7754, DOI: 10.1053/J.SEMINONCOL.2006.04.003 * |
MENDELSOHN; BASELGA: "Epidermal Growth Factor Receptor Targeting in Cancer", SEMINARS IN ONCOLOGY, vol. 33, pages 369 - 385, XP009096633, DOI: doi:10.1053/j.seminoncol.2006.04.003 |
PAEZ ET AL.: "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", SCIENCE, vol. 304, pages 1497 - 1500, XP002359959, DOI: doi:10.1126/science.1099314 |
ROCHE-LIMA ET AL.: "EGFR targeting of solid tumors", CANCER CONTROL, vol. 14, no. 3, 2007, pages 295 - 304 |
ZHAO: "he p110 alpha isoform of P13K is essential for proper growth factor signaling and oncogenic transformation", PNAS, vol. 103, pages 16296 - 16300, XP002462087, DOI: doi:10.1073/pnas.0607899103 |
Also Published As
Publication number | Publication date |
---|---|
JP2011513364A (en) | 2011-04-28 |
US20140161722A1 (en) | 2014-06-12 |
CA2716518A1 (en) | 2009-09-11 |
CN101959533A (en) | 2011-01-26 |
AU2009221164A1 (en) | 2009-09-11 |
AU2009221164B2 (en) | 2012-07-26 |
RU2496500C2 (en) | 2013-10-27 |
BRPI0908049A2 (en) | 2015-08-11 |
KR20100131446A (en) | 2010-12-15 |
JP2014040446A (en) | 2014-03-06 |
EP2259800B1 (en) | 2014-05-07 |
ES2471452T3 (en) | 2014-06-26 |
MX2010009743A (en) | 2010-09-28 |
WO2009109605A1 (en) | 2009-09-11 |
JP5778735B2 (en) | 2015-09-16 |
CN105343102A (en) | 2016-02-24 |
PL2259800T3 (en) | 2014-09-30 |
US20110033453A1 (en) | 2011-02-10 |
RU2013132018A (en) | 2015-01-20 |
PT2259800E (en) | 2014-08-06 |
EP2599499A1 (en) | 2013-06-05 |
EP2259800A1 (en) | 2010-12-15 |
RU2010140435A (en) | 2012-04-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2259800B1 (en) | Use of 5-(2,6-di-morpholin-4-yl-pyrimidin-4-yl)-4-trifluoromethyl-pyridin-2-ylamine for the treatment of non small cell lung carcinoma with acquired resistance to epidermal growth factor receptor (EGFR) modulators. | |
KR101950044B1 (en) | Combinations of akt inhibitor compounds and vemurafenib, and methods of use | |
EP2182948B1 (en) | Use of imidazoquinolines for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members | |
US9295676B2 (en) | Mutation mimicking compounds that bind to the kinase domain of EGFR | |
US20180325883A1 (en) | Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members | |
JP2017061445A (en) | Novel combination use of 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione and egfr tyrosine kinase inhibitors | |
AU2011265510A1 (en) | Use of imidazoquinolines for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members | |
AU2015203865A1 (en) | Use of 2-carboxamide cycloamino urea derivatives in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 2259800 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
17P | Request for examination filed |
Effective date: 20131115 |
|
RBV | Designated contracting states (corrected) |
Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR |
|
17Q | First examination report despatched |
Effective date: 20150908 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20160319 |